Kei Miyakawa

Kei Miyakawa

Auto-generated profile, based on publicly available information

Kei Miyakawa

Influenza Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
YYYutaro Yamaoka
Yutaro Yamaoka
SMSatoko MATSUNAGA
Satoko MATSUNAGA
Jeremiah Sundararaj StanleyrajJeremiah Sundararaj Stanleyraj
Jeremiah Sundararaj Stanleyraj
MNMayuko Nishi
Mayuko Nishi
KMKei Miyakawa
Kei Miyakawa
ARAkihide Ryo
Akihide Ryo

5 April 2022 in Autophagy
Verified
Journal Article
Closed access
KMKei Miyakawa
Kei Miyakawa
Jeremiah Sundararaj StanleyrajJeremiah Sundararaj Stanleyraj
Jeremiah Sundararaj Stanleyraj
MOMichinaga Ogawa
Michinaga Ogawa
MNMayuko Nishi
Mayuko Nishi
MOMakoto Ohnishi
Makoto Ohnishi
ARAkihide Ryo
Akihide Ryo
Although the involvement of macroautophagy/autophagy in hepatitis B virus (HBV) infection has become clearer recently, whether selective autophagy plays an important role in suppressing HBV remains uncertain. We recently found that LGALS9 (galectin 9) is an interferon (IFN)-inducible protein involved in the suppression of HBV replication. Expression of LGALS9 in HBV-infected cells causes the formation of cytoplasmic puncta that degrade the HBV core protein (HBc) in conjunction with RSAD2/viperin, another IFN-inducible protein. LGALS9 binds to HBc via RSAD2 and promotes the autoubiquitination of RNF13 (ring finger protein 13) to recruit SQSTM1/p62, resulting in the formation of LC3-positive autophagosomes that degrade HBc. Both LGALS9 and RSAD2 are encoded by IFN-stimulated genes that act synergistically to induce HBc proteolysis in HBV-infected hepatocytes in an IFN-dependent manner. These results reveal a crosstalk mechanism between the innate immune system and selective autophagy during viral infection.

18 August 2022 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
KMKei Miyakawa
Kei Miyakawa
HKHideaki Kato
Hideaki Kato
NONorihisa Ohtake
Norihisa Ohtake
Jeremiah Sundararaj StanleyrajJeremiah Sundararaj Stanleyraj
Jeremiah Sundararaj Stanleyraj
ARAkihide Ryo
Akihide Ryo
The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has raised concerns regarding vaccine effectiveness. We investigated humoral and cellular immune responses against SARS-CoV-2 in healthcare workers before and after a third (booster) dose of the BNT162b2 messenger RNA vaccine. It significantly enhanced both humoral and cellular immunity in previously uninfected individuals. However, cellular immunity was not enhanced in previously infected persons, suggesting that 3 antigenic stimuli by vaccination or natural infection reached a plateau of cellular immunity. Even with reinforced immunity to SARS-CoV-2, we confirmed several postbooster breakthrough cases caused by the Omicron variant.

18 December 2024 in Viruses
Verified
Journal Article
Open access
PDF file
TOTakashi Okura
Takashi Okura
TTTatsuki Takahashi
Tatsuki Takahashi
TKTaichi Kameya
Taichi Kameya
FMFuminori Mizukoshi
Fuminori Mizukoshi
YNYusuke Nakai
Yusuke Nakai
ARAkihide Ryo
Akihide Ryo
Numerous host factors function as intrinsic antiviral effectors to attenuate viral replication. MARCH8 is an E3 ubiquitin ligase that has been identified as a host restriction factor that inhibits the replication of various viruses. This study elucidated the mechanism by which MARCH8 restricts respiratory syncytial virus (RSV) replication through selective degradation of the viral small hydrophobic (SH) protein. We demonstrated that MARCH8 directly interacts with RSV-SH and catalyzes its ubiquitination at lysine 13, leading to SH degradation via the ubiquitin-lysosomal pathway. Functionally, MARCH8 expression enhances RSV-induced apoptosis through SH degradation, ultimately reducing viral titers. Conversely, an RSV strain harboring the SH-K13R mutation exhibited prolonged SH protein stability and attenuated apoptosis in infected cells, even in the presence of MARCH8. Targeted depletion of MARCH8 enhances cellular survival and potentially increases viral persistence. These findings demonstrate that MARCH8 promotes the early elimination of virus-infected cells by abrogating the anti-apoptotic function of SH, thereby reducing viral transmission. Our study provides novel insights into the interplay between host restriction factors and viral evasion strategies, potentially providing new therapeutic approaches for RSV infections.

10 May 2021 in medRxiv
Verified
Preprint
Open access
PDF file
KMKei Miyakawa
Kei Miyakawa
SJSundararaj Stanleyraj Jeremiah
Sundararaj Stanleyraj Jeremiah
HKHideaki Kato
Hideaki Kato
YYYutaro Yamaoka
Yutaro Yamaoka
HGHirofumi Go
Hirofumi Go
ARAkihide Ryo
Akihide Ryo
The uncontrolled spread of the COVID-19 pandemic has led to the emergence of different SARS-CoV-2 variants across the globe. The ongoing global vaccination strategy to curtail the COVID-19 juggernaut, is threatened by the rapidly spreading Variants of Concern (VOC) and other regional mutants, which are less responsive to neutralization by infection or vaccine derived antibodies. We have previously developed the hiVNT system which detects SARS-CoV-2 neutralizing antibodies in sera in less than three hours. In this study, we modify the hiVNT for rapid qualitative screening of neutralizing antibodies (nAb) to multiple variants of concern (VOC) of SARS-CoV-2, and assess the neutralizing efficacy of the BNT162b2 mRNA vaccine on seven epidemiologically relevant SARS-CoV-2 variants. Here we show that the BNT162b2 mRNA vaccine can activate humoral immunity against the major SARS-CoV-2 mutants that are currently in circulation. Albeit a small sample size, we observed that one dose of vaccine was sufficient to elicit a protective humoral response in previously infected people. Using a panel of seven SARS-CoV-2 variants and a single prototype virus, our modified hiVNT would be useful for large-scale community wide testing to detect protective immunity that may confer vaccine/immune passport in the ongoing COVID-19 pandemic.

Verified
Journal Article
Open access
PDF file
YHYasuyoshi Hatayama
Yasuyoshi Hatayama
KMKei Miyakawa
Kei Miyakawa
YKYayoi Kimura
Yayoi Kimura
KHKazuo Horikawa
Kazuo Horikawa
KHKouichi Hirahata
Kouichi Hirahata
ARAkihide Ryo
Akihide Ryo
Post-acute sequelae of SARS-CoV-2 infection (PASC), commonly known as “Long COVID”, represents a significant clinical challenge characterized by persistent symptoms following acute COVID-19 infection. We conducted a comprehensive retrospective cohort study to identify serum autoantibody biomarkers associated with PASC. Initial screening using a protein bead array comprising approximately 20,000 human proteins identified several candidate PASC-associated autoantibodies. Subsequent validation by enzyme-linked immunosorbent assay (ELISA) in an expanded cohort—consisting of PASC patients, non-PASC COVID-19 convalescents, and pre-pandemic healthy controls—revealed two promising biomarkers: autoantibodies targeting PITX2 and FBXO2. PITX2 autoantibodies demonstrated high accuracy in distinguishing PASC patients from both non-PASC convalescents (area under the curve [AUC] = 0.891) and healthy controls (AUC = 0.866), while FBXO2 autoantibodies showed moderate accuracy (AUC = 0.762 and 0.786, respectively). Notably, the levels of these autoantibodies were associated with several PASC symptoms, including fever, dyspnea, palpitations, loss of appetite, and brain fog. The identification of PITX2 and FBXO2 autoantibodies as biomarkers not only enhances our understanding of PASC pathophysiology but also provides promising candidates for further investigation.